Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease

References

• Bader LA, Elewa H. The impact of genetic and non-genetic factors on warfarin dose prediction in MENA region: a systematic review. PLoS One. 2016;11(12):e0168732. doi:10.1371/journal.pone.0168732
   PubMed Web of Science ®Google Scholar
• Borges JB, Hirata TD, Cerda A, et al. Polymorphisms in genes encoding metalloproteinase 9 and lymphotoxin-alpha can influence warfarin treatment. J Pharmacogenomics Pharmacoproteomics. 2015;6:143. doi:10.4172/2153-0645.1000143
   Google Scholar
• Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67–74. doi:10.1016/s0163-7258(96)00140-4
   PubMed Web of Science ®Google Scholar
• Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329–2333. doi:10.1182/blood-2005-03-1108
   PubMed Web of Science ®Google Scholar
• Tavares LC, Marcatto LR, Santos PC. Genotype-guided warfarin therapy: current status. Pharmacogenomics. 2018;19(7):667–685. doi:10.2217/pgs-2017-0207
   PubMed Web of Science ®Google Scholar
• Al-Eitan LN, Almasri AY, Al-Habahbeh SO. Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy. Pharmacogenomics Person Med. 2019;12:1–8. doi:10.2147/pgpm.s189458
   PubMed Web of Science ®Google Scholar
• Kampouraki E, Kamali F. Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation. Expert Opin Drug Metab Toxicol. 2019;15(6):449–458. doi:10.1080/17425255.2019.1623878
   PubMed Web of Science ®Google Scholar
• Eriksson N, Wallentin L, Berglund L, et al. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016;17(13):1425–1439. doi:10.2217/pgs-2016-0061
   PubMed Web of Science ®Google Scholar
• Fawzy AM, Lip GY. Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. Expert Opin Drug Metab Toxicol. 2019;15(5):381–398. doi:10.1080/17425255.2019.1604686
   PubMed Web of Science ®Google Scholar
• Gage BF. Interview about the GIFT Trial, pharmacogenetics, and warfarin. Pharmacogenomics. 2017;18(15):1379–1380. doi:10.2217/pgs-2017-0148
   PubMed Web of Science ®Google Scholar
• Gulseth MP, Grice GR, Dager WE. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm. 2009;66(2):123–133. doi:10.2146/ajhp080127
   PubMed Web of Science ®Google Scholar
• Johnson J, Caudle K, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397–404. doi:10.1002/cpt.668
   PubMed Web of Science ®Google Scholar
• Millican EA, Lenzini PA, Milligan PE, et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007;110(5):1511–1515. doi:10.1182/blood-2007-01-069609
   PubMed Web of Science ®Google Scholar
• Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc. 2015;25(1):33–41. doi:10.1016/j.tcm.2014.09.001
   PubMed Web of Science ®Google Scholar
• Mak M, Lam C, Pineda SJ, et al. Pharmacogenetics of warfarin in a diverse patient population. J Cardiovasc Pharmacol Ther. 2019;24(6):521–533. doi:10.1177/1074248419843530
   PubMed Web of Science ®Google Scholar
• Emery JD. Pharmacogenomic testing and warfarin: what evidence has the GIFT trial provided? JAMA. 2017;318(12):1110–1112. doi:10.1001/jama.2017.11465
   PubMed Web of Science ®Google Scholar
• Al-Eitan L, Almasri A, Al-Habahbeh S. Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease. Pharmacogenomics Person Med. 2019;12:15–22. doi:10.2147/pgpm.s189838
   PubMed Web of Science ®Google Scholar
• Roden DM, Johnson JA, Kimmel SE, et al. Cardiovascular pharmacogenomics. Circ Res. 2011;109(7):807–820. doi:10.1161/circresaha.110.230995
   PubMed Web of Science ®Google Scholar
• Cha P, Mushiroda T, Takahashi A, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet. 2010;19(23):4735–4744. doi:10.1093/hmg/ddq389
   PubMed Web of Science ®Google Scholar
• Al-Eitan L, Almasri A, Khasawneh R. Impact of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation therapy. Genes. 2018;9(12):578. doi:10.3390/genes9120578
   PubMed Web of Science ®Google Scholar
• Laxton R, Pearce E, Kyriakou T, Ye S. Association of the lymphotoxin-α gene Thr26Asn polymorphism with severity of coronary atherosclerosis. Genes Immun. 2005;6(6):539–541. doi:10.1038/sj.gene.6364236
   PubMed Web of Science ®Google Scholar
• Wang X, Cheng S, Brophy VH, et al. A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations. Stroke. 2009;40(3):683–695. doi:10.1161/strokeaha.108.524587
   PubMed Web of Science ®Google Scholar
• Liu Y, Sheng H, Lu L, et al. Haplotype-based association of four lymphotoxin-alpha gene polymorphisms with the risk of coronary artery disease in Han Chinese. Tohoku J Exp Med. 2011;224(2):119–125. doi:10.1620/tjem.224.119
   PubMed Web of Science ®Google Scholar
• Pouladi N, Bime C, Garcia JG, Lussier YA. Complex genetics of pulmonary diseases: lessons from genome-wide association studies and next-generation sequencing. Transl Res. 2016;168:22–39. doi:10.1016/j.trsl.2015.04.016
   PubMed Web of Science ®Google Scholar
• Beitelshees AL, Navare H, Wang D, et al. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet. 2009;2(4):362–370. doi:10.1161/circgenetics.109.857839
   PubMed Web of Science ®Google Scholar
• Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008;112(4):1022–1027. doi:10.1182/blood-2008-01-134247
   PubMed Web of Science ®Google Scholar
• Nolan D, Kraus WE, Hauser E, et al. Genome-wide linkage analysis of cardiovascular disease biomarkers in a large, multigenerational family. PLoS One. 2013;8(8):e71779. doi:10.1371/journal.pone.0071779
   PubMed Web of Science ®Google Scholar
• Standaard Af handling cumarine interacties; 2003. Available from: www.fnt.nl. Accessed December 23, 2005.
   Google Scholar
• Al-Eitan LN, Elsaqa BZ, Almasri AY, et al. Influence of PSRC1, CELSR2, and SORT1 gene polymorphisms on the variability of warfarin dosage and susceptibility to cardiovascular disease. Pharmacogenomics Person Med. 2020;13:619. doi:10.2147/PGPM.S274246
   PubMed Web of Science ®Google Scholar
• International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–764. doi:10.1056/NEJMoa0809329
   PubMed Web of Science ®Google Scholar
• Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690–1698. doi:10.1001/jama.287.13.1690
   PubMed Web of Science ®Google Scholar
• Panoulas VF, Nikas SN, Smith JP, et al. Lymphotoxin 252AG polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(11):1550–1556. doi:10.1136/ard.2007.082594
   PubMed Web of Science ®Google Scholar
• Clarke R, Xu P, Bennett D, et al. Lymphotoxin-α gene and risk of myocardial infarction in 6928 cases and 2712 controls in the ISIS Case-Control Study. PLoS Genet. 2006;2(7):e107. doi:10.1371/journal.pgen.0020107
   PubMed Web of Science ®Google Scholar
• Liu R, Cao J, Zhang Q, et al. Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement. Medicine. 2017;96. doi:10.1097/md.0000000000005658
   Web of Science ®Google Scholar
• Al-Eitan LN, Almasri AY, Khasawneh RH. Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy. Saudi Pharm J. 2019;27(4):484–490. doi:10.1016/j.jsps.2019.01.011
   PubMed Web of Science ®Google Scholar
• Piatkov I, Jones T, Mcle M. Drug interactions, pharmacogenomics and cardiovascular complication. Drug Discov. 2013;75. doi:10.5772/48423
   Google Scholar
• Gamazon ER, Konkashbaev A, Derks EM, et al. Evidence of selection on splicing-associated loci in human populations and relevance to disease loci mapping. Sci Rep. 2017;7(1):1–15. doi:10.1038/s41598-017-05744-9
   PubMed Web of Science ®Google Scholar
• Cavallari LH. Time to revisit warfarin pharmacogenetics. Future Cardiol. 2017;13:511–513. doi:10.2217/fca-2017-0061
   PubMed Web of Science ®Google Scholar
• Tang Q, Zou H, Guo C, Liu Z. Outcomes of pharmacogenetics-guided dosing of warfarin: a systematic review and meta-analysis. Int J Cardiol. 2014;175(3):587–591. doi:10.1016/j.ijcard.2014.06.031
   PubMed Web of Science ®Google Scholar
• Al-Eitan L, Haddad Y. Emergence of pharmacogenomics in academic medicine and public health in Jordan: history, present state and prospects. Curr Pharmacogenomics Person Med. 2014;12:167–175. doi:10.2174/1875692113666150115221210
   Google Scholar